UNASSIGNED: Children with progressive myopia (6-16 years; n = 153) were randomized to receive 0.01% atropine eye drops or a placebo (2:1 ratio) instilled daily over 2 years, followed by a 1-year washout (no eye drop use). Optical coherence tomography imaging of the choroid was conducted at the baseline, 2-year (end of treatment phase), and 3-year (end of washout phase) visits. The main outcome measure was the subfoveal ChT. Secondary measures include the CVI.
UNASSIGNED: During the treatment phase, the subfoveal choroids in both treatment and control groups thickened by 12-14 µm (group difference P = 0.56). During the washout phase, the subfoveal choroids in the placebo group continued to thicken by 6.6 µm (95% confidence interval [CI] = 1.7 to 11.6), but those in the atropine group did not change (estimate = -0.04 µm; 95% CI = -3.2 to 3.1). Participants with good axial eye growth control had greater choroidal thickening than the fast-progressors during the treatment phase regardless of the treatment group (P < 0.001), but choroidal thickening in the atropine group\'s fast-progressors was not sustained after stopping eye drops. CVI decreased in both groups during the treatment phase, but increased in the placebo group after treatment cessation.
UNASSIGNED: On average, compared to placebo, 0.01% atropine eye drop treatment did not cause a differential rate of change in ChT during treatment, but abrupt cessation of long-term 0.01% atropine eye drops may disrupt normal choroidal thickening in children.
■进行性近视儿童(6-16岁;n=153)被随机分配接受0.01%阿托品滴眼液或安慰剂(2:1比例),每天滴注2年,然后是1年冲洗(不使用滴眼液)。在基线时对脉络膜进行光学相干断层扫描成像,2年(治疗阶段结束),和3年(冲洗阶段结束)访问。主要结果指标是中心凹下ChT。次要措施包括CVI。
■在治疗阶段,治疗组和对照组的中央凹下脉络膜增厚12-14µm(组间差异P=0.56).在冲洗阶段,安慰剂组的中央凹下脉络膜继续增厚6.6µm(95%置信区间[CI]=1.7至11.6),但阿托品组没有变化(估计值=-0.04µm;95%CI=-3.2~3.1).无论治疗组如何,眼轴生长控制良好的参与者在治疗阶段脉络膜增厚大于快速进展者(P<0.001),但阿托品组快速进展者的脉络膜增厚在停止滴眼液后没有持续。治疗期间两组CVI均下降,但安慰剂组在治疗停止后增加。
■平均而言,与安慰剂相比,0.01%阿托品滴眼液治疗期间未引起ChT差异变化率,但长期停用0.01%阿托品滴眼液可能会破坏儿童正常的脉络膜增厚.